XML 94 R81.htm IDEA: XBRL DOCUMENT v3.25.0.1
Income Taxes - Schedule of Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Deferred tax assets:    
Net operating loss carryforwards $ 587,528 $ 574,737
Research and other credits 135,871 144,128
Net capital loss carryforwards 39,648 39,655
Operating lease liabilities 22,767 25,384
Stock-based compensation 19,619 19,447
Capitalized research and development costs 45,607 34,675
Liability related to the sale of future royalties 2,020 6,729
Other 9,402 13,863
Deferred tax assets before valuation allowance 862,462 858,618
Valuation allowance for deferred tax assets (859,084) (854,528)
Total deferred tax assets 3,378 4,090
Deferred tax liabilities:    
Operating lease right-of-use assets (1,835) (3,824)
Investment in foreign subsidiary (511) (521)
Outside basis difference in Gannet BioChem (1,337) 0
Other (205) (265)
Total deferred tax liabilities (3,888) (4,610)
Total deferred tax liabilities $ (510) $ (520)